<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02147782</url>
  </required_header>
  <id_info>
    <org_study_id>Renal Osteodystrophy</org_study_id>
    <secondary_id>1RT1270,2010CB530400</secondary_id>
    <nct_id>NCT02147782</nct_id>
  </id_info>
  <brief_title>Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency</brief_title>
  <official_title>Continuous Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency in Different Stages</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huadong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Longhua Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic renal insufficiency usually develop secondary osteoporosis or bone
      loss, which is called renal osteodystrophy. Most of the previous studies focused on bone
      metabolism of patients in late stage of chronic renal insufficiency, especially those with
      chronic dialysis. In this study, bone metabolism of patients in different stages of chronic
      renal insufficiency will be observed to reveal the mechanism of development of renal
      osteodystrophy and provide clues for early intervention on renal osteodystrophy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, patients with chronic renal insufficiency (CKD1-5, defined by glomerular
      filtration rate，GFR) and healthy people as control will be recruited (50/group, total 300).
      Blood urea nitrogen, creatinine,lumbar and hip bone mineral density, bone turnover
      biochemical markers including serum total propeptide of type I procollagen（PINP）, bone
      alkaline phosphatase（BALP）, bone Gla-protein (BGP) and β-CrOSSlaps（β-CTX）, serum calcium and
      phosphorus and related regulators including fibroblast growth factor 23 (FGF23),
      25-hydroxyl-Vitamin D （25-OH-VitD）, parathyroid hormone（PTH） will be detected. The
      relationship between kidney function and bone turnover, and the rules throughout the
      development process of renal osteodystrophy will be analysed.The micro
      ribonucleotide（miRNA）array will also be performed to screen the biomarkers of renal
      osteodystrophy in different stage.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>bone metabolism (bone mineral density and serum bone turnover biomarkers)</measure>
    <time_frame>1 day after enrollment</time_frame>
    <description>lumbar (L1-4 as well as total) and hip (neck, troch, inter and word's) bone mineral density will be recorded by dual energy X-ray absorptiometry. Serum bone turnover biomarkers including total PINP, BGP, BALP and β-CTx will be detected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kidney function （blood creatinine and urea nitrogen,glomerular filtration rate）</measure>
    <time_frame>1 day after enrollment</time_frame>
    <description>CKD1-5 will be graded by glomerular filtration rate,and blood creatinine and urea nitrogen will be detected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium and phosphorus metabolism (serum calcium and phosphorus,calcium-phosphorus product, FGF23, PTH and 25-OH-VitD)</measure>
    <time_frame>1 day after enrollment</time_frame>
    <description>Serum calcium and phosphorus will be detected and the calcium-phosphorus product will be calculated.Factors which are related with calcium and phosphorus including FGF23, PTH and 25-OH-VitD will be detected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MicroRNA array</measure>
    <time_frame>1 day after enrollment</time_frame>
    <description>Blood plasma will be collected for microRNA array analysis to find specific biomarkers for each stage.We will also try to find biomarkers for better definitions of chronic renal insufficiency and renal osteodystrophy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Baseline information （height, weight, sex）</measure>
    <time_frame>1 day after enrollment</time_frame>
  </other_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Chronic Renal Insufficiency</condition>
  <condition>Renal Osteodystrophy</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>Healthy people from physical examination centers are recruited as controls.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD1</arm_group_label>
    <description>with clinical one or more symptoms and signs of kidney injury listed as below：
Urinary albumin ( urinary albumin excretion rate≥30 mg/24 h.albumin-creatinine ratio≥3mg/mmol)
urinary sediments abnormality
renal tubular lesions
renal histological abnormalities
abnormal structure showed by imaging
history of renal transplantation
GFR≥90（ml/min/1.73m²)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD2</arm_group_label>
    <description>with clinical symptoms and signs of kidney injury, and 60&lt;=GFR&lt;=89（ml/min/1.73m²)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD3</arm_group_label>
    <description>with clinical symptoms and signs of kidney injury, and 30&lt;=GFR&lt;=59（ml/min/1.73m²)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD4</arm_group_label>
    <description>with clinical symptoms and signs of kidney injury, and 15&lt;=GFR&lt;=29（ml/min/1.73m²)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD5</arm_group_label>
    <description>with clinical symptoms and signs of kidney injury, and GFR&lt;15（ml/min/1.73m²)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and plasma of cases and controls
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cases groups (CKD-5) are recruited from inpatients and outpatients in the 4 centers.

        Controls are recruited from community samples and physical examination population.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 20-50 years old

          2. chronic renal insufficiency (Control: normal kidney function; Case: CKD 1-5)

          3. be willing to and be able to join in the study and signed informed consent

          4. have not accepted systematical treatment on bone loss or osteoporosis

        Exclusion Criteria:

          1. allergies

          2. secondary osteoporosis caused by other diseases.

          3. postmenopausal women

          4. mental illness or psychosis

          5. patients with bone fracture and need surgery treatment

          6. taking any medicine that will affect bone metabolism for a long time and can not stop

          7. women during pregnant stage and breast-feed stage

          8. with deformity or disability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongjun Wang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanhgai University of TCM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongjun Wang, MD,PhD</last_name>
    <phone>86-21-64385700</phone>
    <email>yjwang88@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bing Shu, PhD</last_name>
    <phone>86-21-64386239</phone>
    <email>shubing523@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anhui Province Hospital of TCM</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shunjin Hu</last_name>
      <phone>0551-62838661</phone>
    </contact>
    <investigator>
      <last_name>Shunjin Hu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital of TCM</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Longhua hospital affiliated to Shanghai University of TCM</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaofeng Li, PhD</last_name>
      <phone>86-21-64395700</phone>
      <email>lixiaofeng0409@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiaofeng Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huadong Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai University of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Bing Shu</investigator_full_name>
    <investigator_title>Research Asistant</investigator_title>
  </responsible_party>
  <keyword>chronic renal insufficient, renal osteodystrophy, bone mineral density, bone turnover, kidney function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Chronic Kidney Disease-Mineral and Bone Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

